Skip to main content
SpringerLink
Log in

A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma

  • Original Article
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Background and aims

This study assessed the efficacy and safety of irinotecan (CPT-11) in the treatment of patients with unresectable esophageal carcinoma.

Patients and methods

Ten patients with esophageal squamous cell carcinoma (SCC) and three with adenocarcinoma (AC) were treated with CPT-11. Eight of the 13 patients were pretreated by surgery, radio-, or chemotherapy. CPT-11 was administered in repeated 6-week cycles consisting of CPT-11 once weekly for 4 weeks, followed by a 2-week rest. The starting dose of CPT-11 was 125 mg/m2 given intravenously over 60 min; subsequent doses were adjusted based on tolerance and toxicity. Nine patients were evaluable for response.

Results

Two patients showed a partial response (one SCC, one AC) and two others disease stabilization (one SCC, one AC). The mean time to progression was 3.8 months. Mean survival since study entry was 6.1 months. In the 103 administrations we observed grade 3 or 4 toxicity on six occasions with diarrhea, five with neutropenia, and one with nausea and vomiting. Toxicity required dose reductions in five patients; in two of these patients treatment was stopped because of severe toxicity. No treatment related deaths occurred.

Conclusion

CPT-11 as single-agent therapy is modestly effective against squamous cell cancer of the esophagus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Thomas RM, Sobin LH (1995) Gastrointestinal cancer. Cancer 75:154–170

    CAS  PubMed  Google Scholar 

  2. Bareiß D, Stabenow R, Müller R, et al (2002) Current epidemiology of cancers of the esophagus and cardia in Germany. Dtsch Med Wochenschr 127:1367–1374

    Article  PubMed  Google Scholar 

  3. Higenberg AD, Carey RW, Wilkins EW Jr, et al (1988) Preoperative chemotherapy, surgical resection, and selective postoperative therapy for squamous cell carcinoma of the esophagus. Ann Thorac Surg 45:357–363

    PubMed  Google Scholar 

  4. Ross P, Nicolson M, Cunningham J, et al (2002) Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion 5-fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20:1996–2004

    Article  PubMed  Google Scholar 

  5. Hsiang YH, Hertzberg R, Hecht S, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:1473–1478

    Google Scholar 

  6. Hsiang YH, Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722–1726

    CAS  PubMed  Google Scholar 

  7. Schneider E, Hsiang YH, Liu LF (1990) DNA topoisomerases as anticancer drug targets. Adv Pharmacol 21:149–183

    PubMed  Google Scholar 

  8. Hsiang YH, Wu HY, Liu LF (1988) Topoisomerases: novel therapeutic targets in cancer chemotherapy. Biochem Pharmacol 37:1801–1802

    Article  PubMed  Google Scholar 

  9. Ilson DH, Saltz LB, Enzinger PC, et al (1999) Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 17:3270–3275

    PubMed  Google Scholar 

  10. Ajani JA, Baker J, Pisters P, et al (2002) Phase II trial of weekly CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastrooesophageal junction carcinoma. Cancer 94:641–646

    Article  PubMed  Google Scholar 

  11. Hecht JR, Parson LS, Rosen LS (1999) A phase II trial of irinotecan (CPT-11) in patients with adenocarcinoma of the esophagus and gastric cardia. Proc Am Soc Clin Oncol 18:287a

    Google Scholar 

  12. Scherübl H, Scherer H, Hoffmeister B (2002) Second esophageal cancers in head and neck cancer patients. N Engl J Med 346:1416–1417

    Article  Google Scholar 

  13. Perng RP, Shih JF, Chen YM, Chou KC, Lee YC, Tsai CM (2002) A phase II study of single-agent docetaxel chemotherapy for non-small cell lung cancer. Jpn J Clin Oncol 30:429–434

    Article  Google Scholar 

  14. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP (1994) Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86:1086–1091

    PubMed  Google Scholar 

  15. Murthy SK, Prabhakaran PS, Chandeshekar M, et al (1990) Neoadjuvant cis-DDP in esophageal cancers: An experience at a regional cancer center in India. J Surg Oncol 45:173–176

    PubMed  Google Scholar 

  16. Bleiberg H, Jacob J, Bedenne L, et al (1991) Randomized phase II trial of 5-fluorouracil and cisplatinum versus cisplatinum alone in advanced esophageal cancer. Proc Am Soc Clin Oncol 10:145a

    Google Scholar 

  17. Edzinli EZ, Gelber R, Desai DV, et al (1980) Chemotherapy of advanced esophageal carcinoma: Eastern cooperative oncology experience. Cancer 46:2149–2153

    PubMed  Google Scholar 

  18. Bidoli P, Stani SC, De Candis D, Cortinovis D, Parra HS, Bajetta E (2001) Single-agent chemotherapy with vinorelbine for pretreated or metastatic squamous cell carcinoma of the esophagus. Tumori 87:299–302

    PubMed  Google Scholar 

  19. Ilson DH, Bains M, Ginsberg RJ, et al (1997) Neoadjuvant therapy of esophageal cancer. Surg Oncol Clin N Am 6:723–740

    PubMed  Google Scholar 

  20. Conti JA, Kemeny NE, Saltz LB, et al (1996) Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709–715

    Google Scholar 

  21. Rougier P, Bugat R, Douillard JY, et al (1997) Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251–260

    Google Scholar 

  22. Futatsuki K, Wakui A, Nakao I, et al (1994) Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn J Cancer Chemother 21:1033–1038

    Google Scholar 

  23. Murphy BA, Douglas S, Cmelak A, et al (2000) Phase II trial of irinotecan (CPT-11) in metastatic or recurrent squamous cell carccinoma of the head and neck (SSCHN). Proceedings of the 5th International Conference on Head and Neck, vol 5, pp 108

  24. Fukuola M, Niitani H, Suzuki A, et al (1992) A phase II study of CPT-11, a new derivate of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10:16–20

    CAS  PubMed  Google Scholar 

  25. Le Chevalier T, Ibrahim N, Chomy P, et al (1997) A phase II study of irinotecan (CPT-11) in patients with small-cell lung cancer progressing after initial response to first-line chemotherapy. Proc Am Soc Clin Oncol 16:450a

    Google Scholar 

  26. Verschraegen CF, Levy T, Kudelka AP, et al (1997) Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 15:625–331

    PubMed  Google Scholar 

  27. Sugiyama T, Nishida T, Ookura N, et al (1997) Is CPT-11 useful as a salvage chemotherapy for recurrent ovarian cancer? Proc Am Soc Clin Oncol 16:378a

    Google Scholar 

  28. Rothenberg ML, Eckardt JR, Kuhn JG, et al (1996) Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128–1135

    Google Scholar 

  29. Pitot HC, Wender D, O'Connel MJ, et al (1994) A phase II trial of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group (NCCTG) study. Proc Am Soc Clin Oncol 13:573a

    Google Scholar 

Download references

Acknowledgements

This research was supported in part by a grant from Aventis Pharma Germany.

Author information

Authors and Affiliations

  1. Medical Clinic I, University Hospital Benjamin Franklin, Hindenburgdamm 30, 12200, Berlin, Germany

    F. Mühr-Wilkenshoff, E.-O. Riecken, M. Zeitz & H. Scherübl

  2. Department of Radiotherapy, University Hospital Benjamin Franklin, Hindenburgdamm 30, 12200, Berlin, Germany

    W. Hinkelbein

  3. Department of Radiology, University Hospital Benjamin Franklin, Hindenburgdamm 30, 12200, Berlin, Germany

    I. Ohnesorge & K. J. Wolf

Authors
  1. F. Mühr-Wilkenshoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Hinkelbein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Ohnesorge
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. J. Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E.-O. Riecken
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Zeitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H. Scherübl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Scherübl.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mühr-Wilkenshoff, F., Hinkelbein, W., Ohnesorge, I. et al. A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. Int J Colorectal Dis 18, 330–334 (2003). https://doi.org/10.1007/s00384-002-0464-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-002-0464-x

Keywords

Search

Navigation